MEDITCARE

Payments for Covered Outpatient Drugs Exceed Providers’ Cost
Abbreviation

AMP      Average Manufacturer Price
AWP      Average Wholesale Price
BBRA     Balanced Budget Refinements Act of 1999
BESS     Part B Extract and Summary System
BIPA     Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000
CMS      Centers for Medicare and Medicaid Services
DME      Durable Medical Equipment
DOD      Department of Defense
DOJ      Department of Justice
ESRD     End-Stage Renal Disease
FSS      Federal Supply Schedule
GPO      Group Purchasing Organization
HCFA     Health Care Financing Administration
HCPCS    HCFA Common Procedure Coding System
HHS      Health and Human Services
NDC      National Drug Code
OBRA     Omnibus Budget Reconciliation Act
OIG      Office of the Inspector General
PBM      Pharmacy Benefits Manager
PHS      Public Health Service
VA       Department of Veterans’ Affairs
WAC      Wholesale Acquisition Cost
September 21, 2001

Congressional Committees

While Medicare does not have a comprehensive outpatient drug benefit, certain drugs and biologicals are covered under part B of the program. In general, drugs are covered if they cannot be self-administered and are related to a physician’s services, such as cancer chemotherapy, or are provided in conjunction with covered durable medical equipment (DME), such as inhalation drugs used with a nebulizer. In addition, Medicare covers selected immunizations and certain drugs that can be self-administered, such as blood clotting factors and some oral drugs used in association with cancer treatment and immunosuppressive therapy. Medicare spending for these drugs totaled almost $4 billion in 1999.

Recent reports by the Department of Health and Human Services’ (HHS) Office of Inspector General (OIG), the Department of Justice (DOJ), and the House Committee on Commerce found that in some cases Medicare’s payments for part B-covered drugs were significantly higher than physicians’ and other providers’ actual costs of acquiring these products. They found that the average wholesale prices (AWP)—the “list prices” or “sticker prices” set by drug manufacturers and used by Medicare to calculate payment rates—were not representative of the actual costs of these drugs to providers. The Health Care Financing Administration (HCFA) initiated steps to reduce Medicare payment for some drugs. The agency issued a program memorandum in September 2000 that authorized

---

1For the remainder of this report, we will refer to part B-covered drugs and biological products, such as clotting factors used to treat hemophilia, as “drugs.”

2Medicare part B or Supplementary Medical Insurance provides coverage for certain physician, outpatient hospital, laboratory, and other services to beneficiaries who pay monthly premiums.

3A nebulizer is a device driven by a compressed air machine. It allows the patient to take medicine in the form of a mist (wet aerosol). It consists of a cup, a mouthpiece attached to a T-shaped part or a mask, and thin, plastic tubing to connect to the compressed air machine.

4The Medicare program payment is 80 percent of the total payment, or $3.2 billion; beneficiaries are responsible for the remaining 20 percent.

5HCFA was renamed the Centers for Medicare and Medicaid Services in June 2001; we continue to refer to the agency as HCFA when discussing actions it took under that name.
the use of prices obtained in DOJ’s investigations of providers’ drug acquisition costs to set Medicare payment rates for a subset of covered drugs, which would have lowered Medicare payment for these products. However, HCFA retracted the original program memorandum in November 2000.

While physicians—particularly oncologists—and other health care providers such as pharmacy suppliers acknowledge that they can purchase drugs for prices lower than Medicare payments, they contend that they need drug payments in excess of their actual costs to compensate for inadequate or nonexistent Medicare payments for administering the drugs. Specifically, oncologists argue that Medicare’s physician payment system does not adequately reimburse them for their costs of administering chemotherapy. Further, they suggest that some providers, particularly those who purchase drugs in low volume, may not have access to low drug prices, because the lowest prices reflect volume discounts and other factors. They assert that beneficiary access could be impaired if Medicare drug payments are reduced.

In a forthcoming report mandated by the Balanced Budget Refinements Act of 1999 (BBRA), we examine the adequacy of Medicare’s physician payments to oncologists. We conclude that the basic methodology HCFA used to establish the fees is sound. We found that payments to oncologists are 8 percent higher than they would have been if the prior charge-based method had been maintained. We also determined that oncologists’ payments relative to their estimated practice expenses are close to the average for all specialties. However, we identify modifications to the basic method that substantially lowered payments for certain services, including most chemotherapy administration. In our report, we make recommendations to improve Medicare’s physician payment system.

The Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA), required that we determine whether Medicare is reimbursing physicians and other providers adequately for covered drugs and related services. It also stipulated that the Medicare program make no

---


reductions to drug payments until we complete our work. As agreed with 
the committees of jurisdiction, our analysis addressed the following 
questions: (1) What are physicians’ costs of providing drugs relative to 
applicable Medicare payments? (2) What are other providers’ costs of 
providing drugs relative to applicable Medicare payments? (3) What are 
the methods that public and private payers use to establish payments for 
providing these drugs? This legislation also directed that we take into 
account the results of the study of oncology physician payments mandated 
by BBRA in evaluating drug acquisition costs relative to their Medicare 
payments.

To answer these questions, we interviewed officials at the Centers for 
Medicare and Medicaid Services (CMS), the Department of Veterans 
Affairs (VA), HHS OIG, and DOJ. We also interviewed and solicited 
information about drug acquisition costs and costs related to drug 
administration from professional associations representing physicians and 
nonphysician providers, such as DME or pharmacy suppliers. We used 
pricing data from pharmaceutical wholesalers, group purchasing 
organizations (GPO), specialty pharmacies, DME pharmacy suppliers, and 
physicians, including several physicians we identified as billing for low 
volumes of Medicare-covered drugs. We attempted to obtain pricing 
information directly from additional major wholesalers and group 
purchasing organizations, but these entities did not provide the 
information we requested by the time we finalized this report. We 
interviewed representatives from large managed care organizations 
regarding the methods they used to purchase or pay for pharmaceuticals, 
as well as the purchase prices they were able to obtain. We also 
interviewed staff members at the companies that publish the major price 
reporting compendia on average wholesale prices for drugs.

We conducted quantitative analyses using data from HCFA and other 
sources. We used 1999 drug claims data from HCFA to determine which 
covered drugs accounted for the most spending and volume. For detailed 
analysis, we selected the 20 drugs with the highest total Medicare 
expenditures and the 20 drugs with the highest volume; the results of our 
analysis indicated that 35 different drugs accounted for 82 percent of total 
Medicare drug spending and 95 percent of total drug units. 9 We obtained 
prices for 31 of the 35 individual drugs. We did our work in accordance 
with generally accepted government auditing standards from January

---

9Volume for a drug is measured in terms of the number of Medicare-allowed services.
Physicians are able to obtain Medicare-covered drugs at prices significantly below current Medicare payments, which are set at 95 percent of AWP. Wholesalers’ and GPOs’ prices that would be generally available to physicians were considerably less than AWP used to establish the Medicare payment for these drugs. The difference between these prices and AWP for physician-administered drugs in our sample varied by drug. For most physician-administered drugs, the average discount from AWP ranged from 13 percent to 34 percent; two physician-administered drugs had discounts of 65 percent and 86 percent. Our survey of physicians who billed Medicare for low volumes of drugs used in cancer treatment indicated they received discounts that were as large as or larger than widely available discounts for 11 of the 16 products for which they were able to provide price information. Physicians are reimbursed under the physician fee schedule for the costs of administering chemotherapy drugs, which account for most of Medicare’s drug spending. HCFA deviated from the basic methodology for determining practice expense payments for certain services, including chemotherapy administration by nonphysicians, which reduced Medicare’s practice expense payment for most chemotherapy administration services. However, even with this alternative methodology, oncologists’ average practice expense payments in 2001 are 8 percent higher than what they would have been had charge-based payments continued.

Other suppliers are also able to purchase drugs at prices that are considerably less than the AWP used to establish the applicable Medicare payment. Pharmacy suppliers were the predominant billers for 10 of the high-expenditure and high-volume Medicare-covered drugs we analyzed. In general, these suppliers provide two types of drugs—drugs administered through DME and covered oral drugs, such as certain immunosuppressives. Widely available prices in 2001 reflected average discounts of 78 percent from the AWP for ipratropium bromide and 85 percent for albuterol, two DME-delivered inhalation therapy drugs that account for most of Medicare payments to pharmacy suppliers. Medicare pays a monthly fee to pharmacy suppliers for dispensing these and certain other respiratory therapy drugs. Also, suppliers generally receive a payment from Medicare for DME and supplies. Although there has been no recent analysis of the adequacy of Medicare’s DME payments, there are indications that the payments may be above current market rates. Wholesaler and GPO prices for two of the high-volume oral drugs averaged
14 percent and 77 percent below AWP. Medicare makes no separate payments for costs associated with supplying or administering oral drugs.

Private and other public payers use differing payment methods for drugs and their administration. Private health plans use their drug-purchase and patient volume to negotiate favorable prices for drugs and the physician and supplier services related to supplying or delivering the drugs. Other public payers also use their purchasing volume along with information about actual transaction prices from private payers to lower their drug payments. VA and certain other government agencies use the Federal Supply Schedule (FSS) prices for drugs.10 State Medicaid programs reimburse for drugs using formulas based on standard price lists but subsequently receive rebates from the manufacturers calculated using the average manufacturer price (AMP), to substantially lower their net prices for drugs.11 Both the FSS and the AMP are derived from actual market transaction data reported by drug manufacturers. In limited instances, VA also uses competitive bidding approaches to obtain lower drug prices, an approach that Medicare has used in limited demonstration projects.

We recommend that the Administrator of CMS take steps to begin reimbursing providers for part B-covered drugs and related services at levels reflecting providers’ acquisition costs using information about actual market transaction prices. We recommend that the CMS Administrator evaluate expanding competitive bidding approaches to setting payment levels. We also recommend that the CMS Administrator closely monitor beneficiary access to covered drugs in light of any changes to reimbursement.

10FSS prices are available to any federal agency that directly procures pharmaceuticals, including VA medical centers, the Department of Defense (DOD), the Bureau of Prisons, the Public Health Service (PHS), and other designated entities such as the District of Columbia, U.S. territorial governments, the Indian Health Service, and some state veterans homes. Manufacturers must also sell brand-name drugs listed on the FSS to four federal drug purchasers—VA, DOD, PHS, and the Coast Guard—at a price at least 24 percent lower than the nonfederal average manufacturer price, a ceiling price that is lower than the FSS price for many drugs.

11State Medicaid programs generally pay pharmacies a dispensing fee for each prescription and physicians a fee for administering the drugs.
Although Medicare reimburses providers for roughly 450 unique drugs under part B, a small number of products accounted for the majority of Medicare spending and volume.\textsuperscript{12} In 1999, the 20 highest expenditure drugs accounted for 75 percent of total Medicare drug spending and the 20 highest volume drugs accounted for 93 percent of total units.\textsuperscript{13} (See tables 1 and 2.) Combined, these two groups of drugs yielded 35 unique drugs, accounting for 82 percent of total drug spending and 95 percent of total drug units.\textsuperscript{14}

\textsuperscript{12}Each covered drug is identified by an alphanumerics code under the HCFA Common Procedure Coding System (HCPCS), which specifies the drug name, method of administration, and dosage.

\textsuperscript{13}Our analysis of drug acquisition costs excluded four high-volume and high-expenditure drugs. Specifically, we excluded a code for “not otherwise classified antineoplastic drugs,” two antihemophilia clotting factors, and a radiopharmaceutical. We could not collect acquisition cost data on “not otherwise classified antineoplastic drugs” because it does not refer to a specific product. The clotting factors, which are typically billed by non-physician suppliers, were not included for two reasons. First, we were unable to obtain adequate pricing information for these products, a problem also encountered by HHS OIG in its prior work on drug reimbursement. Second, these products differ significantly from other pharmaceutical products discussed in this report. Their source material is collected from human donors; their manufacturing, storage, and distribution processes differ from other products; and they are administered to a very small patient population. The excluded radiopharmaceutical, Technetium TC Sestamibi, is used by cardiologists in certain diagnostic imaging procedures. Since Medicare only began requiring data on AWPs to reimburse for radiopharmaceutical products in 2001, these data are currently being developed.

\textsuperscript{14}Units are defined as the number of claims for each drug times the number of units specified by its HCPCS label.
Table 1: Medicare Part B Drugs by Share of Total Medicare Drug Spending, 1999

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Share of total Medicare drug spending (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate (for depot suspension)</td>
<td>15.1</td>
</tr>
<tr>
<td>Epoetin alpha for non-ESRD use</td>
<td>9.5</td>
</tr>
<tr>
<td>Goserelin acetate implant</td>
<td>7.9</td>
</tr>
<tr>
<td>Ipratropium bromide, unit dose form</td>
<td>6.4</td>
</tr>
<tr>
<td>Albuterol, unit dose form</td>
<td>6.3</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>6.2</td>
</tr>
<tr>
<td>Carboplatin</td>
<td>2.9</td>
</tr>
<tr>
<td>Pamidronate disodium</td>
<td>2.8</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>2.0</td>
</tr>
<tr>
<td>Gemcitabine HCl</td>
<td>1.9</td>
</tr>
<tr>
<td>Rituximab</td>
<td>1.8</td>
</tr>
<tr>
<td>Filgrastim (G-CSF) 480 mcg</td>
<td>1.7</td>
</tr>
<tr>
<td>Leucovorin calcium</td>
<td>1.6</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>1.5</td>
</tr>
<tr>
<td>Factor VIII (antihemophilic factor, recombinant)</td>
<td>1.3</td>
</tr>
<tr>
<td>Technetium TC Sestamibi</td>
<td>1.2</td>
</tr>
<tr>
<td>Hylan G-F 20</td>
<td>1.2</td>
</tr>
<tr>
<td>Filgrastim (G-CSF) 300 mcg</td>
<td>1.2</td>
</tr>
<tr>
<td>Not otherwise classified antineoplastic drugs</td>
<td>1.2</td>
</tr>
<tr>
<td>Dolasetron mesylate, injection</td>
<td>1.2</td>
</tr>
<tr>
<td>Subtotal, 20 highest-expenditure drugs and biologicals</td>
<td>74.9</td>
</tr>
<tr>
<td>All other Medicare-covered drugs and biologicals</td>
<td>25.1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>100.0</strong></td>
</tr>
</tbody>
</table>

Source: GAO analysis of data from the Medicare Part B Extract and Summary System (BESS).
Table 2: Medicare Part B Drugs by Share of Total Medicare Units, 1999

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Share of total units (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol, unit dose form</td>
<td>65.8</td>
</tr>
<tr>
<td>Ipratropium bromide, unit dose form</td>
<td>8.2</td>
</tr>
<tr>
<td>Epoetin alpha for non-ESRD use</td>
<td>3.4</td>
</tr>
<tr>
<td>Dolasetron mesylate, injection</td>
<td>3.3</td>
</tr>
<tr>
<td>Albuterol, concentrated form</td>
<td>2.6</td>
</tr>
<tr>
<td>Mycophenolate mofetil, oral</td>
<td>1.7</td>
</tr>
<tr>
<td>Cromolyn sodium, unit dose form</td>
<td>1.2</td>
</tr>
<tr>
<td>Heparin sodium</td>
<td>1.0</td>
</tr>
<tr>
<td>Cyclosporine, oral</td>
<td>0.9</td>
</tr>
<tr>
<td>Ondansetron HCl, injection</td>
<td>0.8</td>
</tr>
<tr>
<td>Tacrolimus, oral</td>
<td>0.7</td>
</tr>
<tr>
<td>Prednisone, oral</td>
<td>0.6</td>
</tr>
<tr>
<td>Acetylcysteine, unit dose form</td>
<td>0.5</td>
</tr>
<tr>
<td>Botulinum toxin, type A</td>
<td>0.5</td>
</tr>
<tr>
<td>Imiglucerase</td>
<td>0.4</td>
</tr>
<tr>
<td>Factor VIII (antihemophilic factor, human)</td>
<td>0.4</td>
</tr>
<tr>
<td>Dexamethasone sodium phosphate</td>
<td>0.4</td>
</tr>
<tr>
<td>Leucovorin calcium</td>
<td>0.3</td>
</tr>
<tr>
<td>Saline solution, sterile</td>
<td>0.3</td>
</tr>
<tr>
<td>Granisetron HCl, injection</td>
<td>0.3</td>
</tr>
<tr>
<td>Subtotal, 20 highest-volume drugs and biologicals</td>
<td>93.3</td>
</tr>
<tr>
<td>All other Medicare-covered drugs and biologicals</td>
<td>6.7</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>100.0</strong></td>
</tr>
</tbody>
</table>

Note: Units are defined as the number of Medicare-allowed services. Each drug has a standard unit dosage specified by the HCPCS code.

Source: GAO analysis of data from BESS.

The drugs provided by physicians account for the largest share of Medicare expenditures for drugs under part B, while billing volume is dominated by the drugs provided by pharmacy suppliers. Drugs provided in the physician office setting accounted for over 75 percent of Medicare spending for drugs in 1999. (See table 3.) Three specialties, hematology/oncology, medical oncology, and urology, bill Medicare primarily for drugs used in the treatment of cancer and represented 80 percent of total Medicare payments to physicians for drugs. By contrast, pharmacy suppliers accounted for over 80 percent of Medicare drug billing volume and less than 20 percent of corresponding payments. Two inhalation therapy drugs dominated these home-administered products, accounting for 88 percent of Medicare volume in the home setting. When the drug is delivered in a physician’s office, Medicare makes a separate
additional payment through the physician fee schedule for the physician or his or her staff administering a drug. When the drug is administered via DME in the home, Medicare pays separately for DME, the drug, and associated supplies as well as a monthly dispensing fee for providing nebulizer drugs.

Table 3: Medicare Part B Drug Spending and Volume by Place of Service, 1999

<table>
<thead>
<tr>
<th>Place of service</th>
<th>Total spending</th>
<th>Share of total spending (percentage)</th>
<th>Total units</th>
<th>Share of total units (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician office</td>
<td>$3,021,662,605</td>
<td>76.2</td>
<td>142,247,564</td>
<td>14.9</td>
</tr>
<tr>
<td>Home</td>
<td>$727,559,447</td>
<td>18.3</td>
<td>759,461,862</td>
<td>79.7</td>
</tr>
<tr>
<td>Other</td>
<td>218,297,305</td>
<td>5.5</td>
<td>51,770,956</td>
<td>5.4</td>
</tr>
<tr>
<td>Total</td>
<td>$3,967,519,357</td>
<td>100.0</td>
<td>953,480,382</td>
<td>100.0</td>
</tr>
</tbody>
</table>

"Other" includes, for example, immunization centers, end-stage renal disease treatment facilities, and independent laboratories.

Note: Medicare’s payment is 80 percent of the allowed amount and the beneficiaries’ share is 20 percent, after they have fulfilled their annual deductible requirements. Units are defined as the number of Medicare-allowed services, as specified by the HCPCS code.

Source: GAO analysis of data from BESS.

Medicare Payments for Drugs Are Based on Published AWPs

Medicare bases its reimbursement to physicians and other providers of drugs on AWP, which is often described as a “list price,” “sticker price,” or “suggested retail price,” reflecting the fact that AWP is not necessarily the price paid by a purchaser or a consistently low or “wholesale” price. AWPs are published for each drug identified by a National Drug Code (NDC). Manufacturers periodically report AWPs for NDCs to publishers of drug pricing data, such as the Medical Economics Company, Inc., which publishes the Red Book, or First Data Bank, which compiles the National Drug Data File. Publishers of AWPs and other drug prices stated that they list the prices as reported to them by the manufacturers. There is no required frequency for manufacturers to report AWPs, but publishers said they attempt to update AWPs at least annually. Medicare carriers, the contractors responsible for paying part B claims, use published AWPs to

15NDCs are the universal product identifiers for drugs for human use; the Food and Drug Administration assigns the first part of the NDC, which identifies the firm that manufactures, repackages, or distributes a drug. Each NDC is specific to a chemical entity, dosage form, manufacturer, strength, and package size. For example, a drug made by one manufacturer, in one form and strength, but in three package sizes, would have three NDCs.
determine the Medicare-allowed amount, or payment level, which is 95 percent of AWP for each HCPCS-coded drug. Because one HCPCS code may have multiple NDCs that match the HCPCS-coded product’s definition, the carriers may determine the Medicare payment by analyzing multiple NDCs.  

Drug Supply Chain Involves Multiple Parties and Arrangements That Influence the Net Cost to the End Purchaser

Pharmaceutical sales and distribution networks can involve multiple entities and purchasing arrangements that affect the actual acquisition price of the drug for the end purchaser that supplies it to a Medicare beneficiary. Physicians and pharmacies can purchase the kinds of drugs covered under Medicare part B from general or specialty pharmaceutical wholesalers or they can have direct purchase agreements with manufacturers. Purchasers may belong to GPOs that pool the purchasing of multiple entities and negotiate prices with wholesalers or manufacturers. GPOs may negotiate different prices for a drug for different end users, such as physicians, pharmacies, or hospitals.

Determining physicians’ or other providers’ actual acquisition cost of drugs is complicated by certain practices in the pharmaceutical marketplace that may result in transaction prices paid at the time of sale that do not reflect the final net cost to the purchaser. For example, manufacturers or wholesalers may offer purchasers rebates based on the volume of products purchased. In addition, manufacturers may establish “chargeback” arrangements for end purchasers, under which the purchaser negotiates a price with the manufacturer that is lower than the price the wholesaler charges for the product. The wholesaler sells the product to the purchaser for the lower price negotiated with the manufacturer, and then asks the manufacturer to pay back the difference between the wholesaler’s price and the negotiated price.

16For single-source drugs (drugs whose manufacturer is the sole source for a given product), Medicare’s payment is 95 percent of the drug’s AWP. For multisource drugs (drugs with generic equivalents or drugs for which there are two or more competing brand-name products), the payment allowance is 95 percent of the lower of (1) the median AWP of all generic forms of the drug or (2) the lowest brand-name product AWP. Within these guidelines, each carrier contracting with Medicare to process claims has discretion to determine which NDCs should be used to calculate the payment rate for each HCPCS code. This can lead to variation in payment amounts among carriers for the same HCPCS-coded drug. By October 1, 2002, all payers, including Medicare, will be required to process and pay drug claims by NDC, rather than HCPCS code, in compliance with the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (P.L. 104-191). 65 Fed. Reg. 50312, 50370 (to be codified at 42 C.F.R. 162.1002(c)).
Physicians are able to obtain drugs at prices significantly below current Medicare reimbursements. The widely available prices available from wholesalers and GPOs for physician-administered drugs we examined were considerably less than AWPs used to establish the Medicare payment. For most of the high-expenditure or high-volume physician-administered drugs we studied and for which we obtained price data, the average widely available discounts from AWP ranged from 13 percent to 34 percent; but two drugs exhibited considerably larger discounts. Physicians we identified as low-volume billers for oncology drugs can also purchase drugs for considerably less than Medicare’s payment. In addition to reimbursement for drugs, physicians are paid separately for services associated with drug administration under the Medicare physician fee schedule. In a separate forthcoming report, we find that Medicare’s basic method for calculating these payments is sound, but it deviated from this method in calculating payments for certain services, including chemotherapy administration. We also find that oncologists’ payments relative to their estimated practice expenses are close to the average for all specialties. In that report, we make recommendations to improve Medicare physician payments for all services.

Among the 31 drugs we analyzed, which accounted for the majority of Medicare spending and volume, 21 were provided almost exclusively by physicians. Physicians providing drugs to treat cancer—the specialties of hematology/oncology, medical oncology, and urology—account for most Medicare claims for 19 of these drugs. Oncologists and groups representing oncologists told us that oncologists can purchase Medicare-covered drugs for less than the Medicare payment amount. Price lists from wholesalers and GPOs show that widely available prices were considerably less than AWPs used to establish the Medicare payment for 18 of these physician-administered cancer drugs, with price information unavailable for one other. (See table 4.) For 16 of the cancer drugs, the average discount from AWP ranged from 13 percent to 34 percent, and two drugs exhibited considerably larger discounts. Prices were available for only one of the two noncancer drugs generally provided by physicians, and


18Of the other high-volume/high-expenditure drugs we analyzed, orthopedic surgeons and neurologists were each the primary billers for a single product.
its average discount from AWP was 18 percent. Certain purchasers may have access to even greater discounts for certain products than the widely available discounts we report here.

Table 4: Widely Available Discounts From AWP for Medicare-Covered Drugs Billed Primarily by Physicians, 2001

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Specialty most frequently billing for drug</th>
<th>Average AWP</th>
<th>Average widely available discount from AWP (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate (for depot suspension)</td>
<td>urology</td>
<td>$618.93</td>
<td>17.6</td>
</tr>
<tr>
<td>Rituximab</td>
<td>oncology</td>
<td>$478.47</td>
<td>19.2</td>
</tr>
<tr>
<td>Goserelin acetate implant</td>
<td>urology</td>
<td>$469.99</td>
<td>21.9</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>oncology</td>
<td>$313.51</td>
<td>22.0</td>
</tr>
<tr>
<td>Filgrastim (G-CSF) 480 mcg</td>
<td>oncology</td>
<td>$300.40</td>
<td>18.0</td>
</tr>
<tr>
<td>Pamidronate disodium</td>
<td>oncology</td>
<td>$279.86</td>
<td>16.8</td>
</tr>
<tr>
<td>Hylan G-F 20</td>
<td>orthopedic surgery</td>
<td>$225.13</td>
<td>17.7</td>
</tr>
<tr>
<td>Filgrastim (G-CSF) 300mcg</td>
<td>oncology</td>
<td>$193.62</td>
<td>18.4</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>oncology</td>
<td>$180.57</td>
<td>19.0</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>oncology</td>
<td>$141.32</td>
<td>22.9</td>
</tr>
<tr>
<td>Carboplatin</td>
<td>oncology</td>
<td>$120.48</td>
<td>20.3</td>
</tr>
<tr>
<td>Gemcitabine HCl</td>
<td>oncology</td>
<td>$112.34</td>
<td>21.3</td>
</tr>
<tr>
<td>Dolasetron mesylate, injection</td>
<td>oncology</td>
<td>$45.02</td>
<td>65.0</td>
</tr>
<tr>
<td>Granisetron HCl</td>
<td>oncology</td>
<td>$19.52</td>
<td>29.3</td>
</tr>
<tr>
<td>Leucovorin calcium</td>
<td>oncology</td>
<td>$18.44</td>
<td>85.6</td>
</tr>
<tr>
<td>Epoetin alpha for non-ESRD use</td>
<td>oncology</td>
<td>$12.91</td>
<td>15.2</td>
</tr>
<tr>
<td>Ondansetron HCl, injection</td>
<td>oncology</td>
<td>$6.41</td>
<td>12.8</td>
</tr>
<tr>
<td>Botulinum toxin type A</td>
<td>neurology</td>
<td>$4.86</td>
<td>n/a</td>
</tr>
<tr>
<td>Imiglucerase</td>
<td>oncology</td>
<td>$3.95</td>
<td>n/a</td>
</tr>
<tr>
<td>Dexamethasone sodium phosphate</td>
<td>oncology</td>
<td>$1.44</td>
<td>14.2</td>
</tr>
<tr>
<td>Heparin sodium</td>
<td>oncology</td>
<td>$0.43</td>
<td>34.4</td>
</tr>
</tbody>
</table>

a"Average AWP" is the average of AWP of each NDC for that product adjusted to the HCPCS-defined dosage.

b"Average widely available discount from AWP" for each drug was calculated by (1) determining the average widely available price(s) for each NDC for that drug, (2) determining the percentage difference between the average widely available price(s) and the AWP for each NDC for that drug, and (3) averaging the percentage differences for all NDCs for that drug.

c"Oncology" specialty includes hematology/oncology and medical oncology.
"Average widely available discount from AWP" in 2001 for this drug is based on a price or prices from a single wholesaler. For these four drugs, we had 2000 data from two or more sources. Those data showed that the average widely available discount from AWP in 2000 was 18.8 percent for Filgrastim (G-CSF) 480 mcg, 17.6 percent for Hylan G-F 20, 19.0 percent for Filgrastim (G-CSF) 300mcg, and 42.2 percent for Dolasetron mesylate, injection.

We were unable to obtain wholesaler or GPO prices for these products.

Source: GAO analysis of data from BESS, the Medical Economics Drug Topics Red Book CD-ROM vol. 21, and wholesaler and GPO price lists.

While physician practices that purchase large volumes of drugs may have access to larger discounts and rebates, low-volume providers can also purchase drugs for markedly less than AWP, and often at additional discounts below widely available prices. 19 (See table 5.) Our survey of physicians who billed Medicare for low volumes of cancer drugs indicated they received discounts that were as large as or larger than widely available discounts for 11 of the 16 products for which they were able to provide price information, although these discounts may not be as high as those obtained by higher-volume purchasers. These practices reported a variety of arrangements for obtaining these drugs, including contracts with manufacturers, wholesalers, or GPOs.

19For example, physicians and other purchasers can obtain lower prices if they make prompt payments.
Table 5: Discounts From AWP Obtained by Physicians Who Billed Medicare for a Low Volume of Selected Drugs, Compared to Widely Available Discounts, 2001

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Low volume billers’ average discount from AWP (percentage)</th>
<th>Average widely available discount from AWP* (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate (for depot suspension)</td>
<td>32.8</td>
<td>17.6</td>
</tr>
<tr>
<td>Rituximab</td>
<td>15.7</td>
<td>19.2</td>
</tr>
<tr>
<td>Goserelin acetate implant</td>
<td>22.3</td>
<td>21.9</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>22.0</td>
<td>22.0</td>
</tr>
<tr>
<td>Filgrastim (G-CSF) (480 mcg)</td>
<td>22.4</td>
<td>18.0c</td>
</tr>
<tr>
<td>Pamidronate disodium</td>
<td>18.0</td>
<td>16.8</td>
</tr>
<tr>
<td>Filgrastim (G-CSF) (300 mcg)</td>
<td>21.7</td>
<td>18.4c</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>25.8</td>
<td>19.0</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>27.1</td>
<td>22.9</td>
</tr>
<tr>
<td>Carboplatin</td>
<td>20.0c</td>
<td>20.3</td>
</tr>
<tr>
<td>Gemcitabine HCl</td>
<td>16.1</td>
<td>21.3</td>
</tr>
<tr>
<td>Dolasetron mesylate, injection</td>
<td>62.0</td>
<td>65.0c</td>
</tr>
<tr>
<td>Granisetron HCl, injection</td>
<td>28.1</td>
<td>29.3</td>
</tr>
<tr>
<td>Leucovorin calcium</td>
<td>90.4</td>
<td>85.6</td>
</tr>
<tr>
<td>Epoetin alpha for non-ESRD use</td>
<td>22.1</td>
<td>15.2</td>
</tr>
<tr>
<td>Ondansetron HCl, injection</td>
<td>26.4</td>
<td>12.8</td>
</tr>
</tbody>
</table>

**“Average widely available discount from AWP” for each drug was calculated by (1) determining the average widely available price(s) for each NDC for that drug, (2) determining the percentage difference between the average widely available price(s) and the AWP for each NDC for that drug, and (3) averaging the percentage differences for all NDCs for that drug.**

**“Low-volume billers’ average discount from AWP” for this drug is based on a price from a single physician.**

**“Average widely available discount from AWP” for this drug is based on a price or prices from a single wholesaler.**

Notes: Out of our sample of 108 physicians, 14 provided us with acquisition cost data for 16 of the 18 cancer treatment drugs we examined. An additional 37 physicians belonged to large, hospital-based or national chain oncology practices that likely had access to widely available drug price discounts. Fifty-six physicians could not be contacted or refused to participate. One physician in the sample did not purchase drugs.

Source: GAO telephone survey of a sample of physicians who billed Medicare for a low volume of cancer drugs in 1999 and AWPs listed in a contemporaneous wholesaler catalog.

**Medicare Pays Physicians for Drug Administration Through the Physician Fee Schedule**

In addition to the AWP-based payment for the drug, physicians receive a payment based on Medicare’s physician fee schedule for administering the drug. The physician fee schedule consists of three components: one to account for physician time and effort to provide the service, one for the expenses of operating the physician practice (including payments reflecting the costs of nonphysician personnel involved in the delivery of services), and one for malpractice expenses. The practice expense...
component was developed with the best available physician-reported data on the actual costs of running their practices. These costs were then allocated to individual services that are provided and billed for, such as office visits and medical procedures.

Oncologists have expressed concerns that certain costs necessary to administer drugs are not fully reimbursed by the practice expense component of Medicare’s physician fee schedule payment. Their representatives told us that certain costs were not reflected in the data originally used to set physician fee schedule payments for drug administration, as changes have occurred in how services are delivered over time. Oncology representatives also indicate concern about the representativeness of the data used to construct the fee schedule. They believe the sample of physician practices that supplied the practice expense data may have been biased by including too many hospital-based oncologists or surgical oncologists, which would understate the practice expenses for chemotherapy services. In addition, the number of oncology practices in the sample is small, increasing the risk that the sample information is not representative.

We have reported previously that the basic methodology for determining physicians’ practice expense payments is reasonable. In a separate forthcoming report, we examine the adequacy of these payments for oncologists. We find that HCFA deviated from the basic methodology for determining practice expense payments for certain services, including chemotherapy administration by nonphysicians. The use of the alternative methodology resulted in a significant reduction in chemotherapy administration service payments compared to what payments would have been had they been calculated under the basic methodology. However, even with this alternative methodology, oncologists’ average practice expense payments in 2001 are 8 percent higher than what they would have been had charge-based payments continued. Further, under the current practice expense methodology, oncologists’ payments relative to their estimated practice expenses are close to the average payment for all

---

20In another study, also mandated by the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (see P.L. 106-554, Appendix F., Sec. 411, 114 Stat. 2763, 2763A-508), we are examining methods CMS may use to collect and employ more current information to modify the physician fee schedule to reflect potential changes in service delivery or costs and more representative data on practice expenses.

specialties. In the separate report, we make recommendations to improve the appropriateness of Medicare physician fee schedule payments for all services.22

Pharmacy suppliers can also obtain drugs such as those administered through the DME benefit at prices far lower than Medicare payment levels. Pharmacy suppliers were the predominant billers for 10 of the drugs in our sample of high-expenditure and high-volume drugs; these drugs included inhalation therapy drugs administered through DME and oral immunosuppressive drugs. Pharmacy suppliers may also administer infusion drugs, such as chemotherapy drugs in the home setting.23 For the inhalation therapy drugs, wholesaler and GPO prices that would be generally available to these suppliers for drugs administered through DME were considerably less than AWPs used to establish the Medicare payment. Wholesaler or GPO price discount information for two of the oral immunosuppressive drugs in our sample was not available, but retail prices for these products from Internet pharmacies were generally below Medicare payment levels. Medicare makes an additional payment for dispensing drugs used in inhalation therapy, but not for drugs used in infusion treatments. Further, Medicare makes a separate payment to DME suppliers for the rental or purchase of the equipment needed to administer the drug, such as nebulizers or infusion pumps, in addition to the payment to the pharmacy supplier for the drug itself. There has been no recent analysis of Medicare’s payments relative to the costs for DME used to administer drugs.


23Like inhalation therapy, infusion therapy, such as therapy for heart failure, can be provided in the home setting using an infusion pump. Infusion therapy involves injection of drugs over time, most often intravenously; Medicare covers infusion pumps and necessary drugs and supplies when it is medically necessary to administer the drug with a durable infusion pump that regulates the rate of infusion. Infusion drugs provided by pharmacy suppliers did not appear as high-volume or high-expenditure products and make up a small percentage of pharmacy suppliers’ aggregate Medicare billing. The 10 drugs on our list provided primarily by pharmacy suppliers accounted for 91 percent of their Medicare payments and 98 percent of their Medicare volume in 1999.
Pharmacy suppliers were the dominant billers for 10 of the highest expenditure or volume drugs paid for under Medicare part B. Among these 10 drugs were five inhalation therapy drugs and four oral immunosuppressive drugs.\textsuperscript{24} Prices available from wholesalers and GPOs were much less than the AWPs used to establish the Medicare payment for the inhalation therapy drugs. (See table 6.) The average discount from AWP in 2001 ranged from 60 percent to 85 percent. These results were consistent with prior studies of the acquisition costs of similar drugs.\textsuperscript{25} Widely available wholesale or GPO prices for two of the oral immunosuppressive drugs involved average discounts from AWP of 14 percent and 77 percent. Although we were unable to obtain 2001 price discount information for two other oral immunosuppressive drugs, a review of prices available from Internet pharmacies found that retail prices available for these products were 13 percent and 8 percent below AWP.

\textsuperscript{24}Sterile saline is the tenth.

\textsuperscript{25}HHS OIG, Medicare Reimbursement of Albuterol (OEI-03-00-00311), June 2000, and Medicare Reimbursement of Prescription Drugs (OEI-03-00-00310), January 2001.
### Table 6: Discounts From AWP for Medicare-Covered Drugs Billed Primarily by DME Pharmacy Suppliers, 2001

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Mode of administration</th>
<th>Average AWP</th>
<th>Average widely available discount from AWP (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipratropium bromide, unit dose form</td>
<td>inhalation</td>
<td>$3.52</td>
<td>78.0[^a]</td>
</tr>
<tr>
<td>Acetylcysteine, unit dose form</td>
<td>inhalation</td>
<td>$0.67</td>
<td>71.8[^a]</td>
</tr>
<tr>
<td>Albuterol, unit dose form</td>
<td>inhalation</td>
<td>$0.50</td>
<td>85.0</td>
</tr>
<tr>
<td>Cromolyn sodium, unit dose form</td>
<td>inhalation</td>
<td>$0.38</td>
<td>69.1</td>
</tr>
<tr>
<td>Albuterol, concentrate</td>
<td>inhalation</td>
<td>$0.15</td>
<td>n/a[^b]</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>oral</td>
<td>$3.10</td>
<td>n/a[^b]</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>oral</td>
<td>$2.53</td>
<td>14.2[^c]</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>oral</td>
<td>$1.55</td>
<td>n/a[^b]</td>
</tr>
<tr>
<td>Prednisone</td>
<td>oral</td>
<td>$0.15</td>
<td>76.7[^c]</td>
</tr>
<tr>
<td>Saline solution, sterile</td>
<td>intravenous, other</td>
<td>$0.71</td>
<td>n/a[^b]</td>
</tr>
</tbody>
</table>

[^a]: "Average AWP" is the average of the AWP of each NDC for that product adjusted to the HCPCS-defined dosage.

[^b]: "Average widely available discount from AWP" for each drug was calculated by (1) determining the average widely available price(s) for each NDC for that drug, (2) determining the percentage difference between the average widely available price(s) and the AWP for each NDC for that drug, and (3) averaging the percentage differences for all NDCs for that drug.

[^c]: "Average discount from AWP" in 2001 for this drug is based on a price from a single wholesaler. For Ipratropium bromide, unit dose form, we had 2000 data from three sources. Those data showed that the average widely available discount from AWP in 2000 was 66.7 percent. For Prednisone we also had 2000 data from only one source.

[^d]: Average discounts from AWP were not available for 2001; average discounts are from 2000.

[^e]: Wholesaler or GPO prices for these products were not available.

Source: GAO analysis of data from BESS, the Medical Economics Drug Topics Red Book CD-ROM vol. 21, and wholesaler and GPO price lists.

---

**Medicare’s Payments to Pharmacy Suppliers for Dispensing Drugs Vary by Class of Drug**

Medicare’s coverage of most drugs provided by pharmacy suppliers is established through the DME benefit; Medicare also covers selected immunizations and certain drugs that can be self-administered, such as blood clotting factors and some oral drugs used in association with cancer treatment and immunosuppressive therapy. The DME benefit covers equipment, such as nebulizers used to administer inhalation therapy drugs for treating respiratory conditions or infusion pumps used to administer...
intravenous drugs, and the supplies and drugs used with it. Medicare also covers and makes a separate payment for drugs and supplies used in conjunction with covered DME. Medicare uses a fee schedule to pay for most DME. DME fees, which are state specific, are based on historical average supplier charges that are adjusted for inflation over time and are subject to national minimum and maximum payment limits. Medicare pays for certain DME on a monthly basis, subject to a maximum number of months, depending upon whether the equipment is rented or purchased. 

Medicare pays a dispensing fee in conjunction with inhalation therapy drugs used in nebulizers, which account for the majority of Medicare volume and spending in the home setting. In 2000, these dispensing fees amounted to over $15 million for 3 million billed dispensing services. Pharmacy suppliers in aggregate received the bulk of their Medicare payments for dispensing the inhalation therapy drugs we analyzed. Unlike many private payers and most state Medicaid programs, Medicare does not pay a dispensing fee to pharmacists or other providers who supply oral drugs. Finally, Medicare neither covers nor reimburses pharmacy suppliers for the costs of clinical services related to providing infusion therapy drugs. We did not analyze the costs of infusion therapy drugs provided in the home setting because they do not account for a substantial share of Medicare drug spending or volume. DME pharmacy suppliers argued that they provide home infusion services to beneficiaries who are too frail to travel to their physicians’ offices for care and need these services in the home. However, such beneficiaries would likely qualify for skilled nursing care under Medicare’s home health benefit—designed to

---

26The DME benefit allows for coverage of DME itself plus “supplies,” including drugs that “must be put directly into the equipment in order to achieve the therapeutic benefit of the durable medical equipment or to assure the proper functioning of the equipment.” (See Medicare Carriers Manual, Part 3, Chapter II—Coverage and Limitations, section 2100.5, Rev. 1564/pp. 2-45.)

27Medicare will make a maximum of 15 monthly payments if the equipment is rented and 13 monthly payments if it is purchased. There are no limits, however, on how long Medicare will pay for one category of nebulizers that requires frequent servicing as long as the equipment is medically necessary.

28Pharmacy suppliers bill Medicare for each month of providing nebulizer drugs to a beneficiary, regardless of the amount of the drug billed, using HCPCS code E0590. The average dispensing fee is currently $5.00 per month of service.
provide clinical care with adequate supervision—which could cover such service costs. 29

Pharmacy suppliers and their representatives said that the profit on the Medicare drug payment is needed to compensate them for their costs related to inhalation and infusion therapy that are not explicitly covered by Medicare. According to these suppliers, these costs include purchasing drugs; all clinical, administrative, and other labor associated with delivering the drugs; billing and collection; facility and employee accreditation; licensing and certifications; and providing printed patient education materials. They said they are currently able to provide these services to Medicare beneficiaries because of their margin on the Medicare drug payments. Suppliers of inhalation and infusion therapies that we spoke with were unable to quantify the costs of these services specific to the provision of drugs or to the different courses of therapy they provide relative to Medicare’s total payment, and we did not identify any other such relevant analysis. Suppliers and their representatives reported to us that the suppliers’ acquisition cost of the drug is only a “nominal” portion of the total cost of providing infusion and inhalation therapy to Medicare patients. Specifically, they indicated that drugs represented roughly a quarter of the total cost of inhalation therapy, and approximately 40 percent of the cost of infusion therapy, excluding the cost of DME.

In this work, we did not analyze suppliers’ costs of supplying DME relative to Medicare’s payment to assess whether those payments also include a profit. However, a prior GAO report indicated two underlying problems with Medicare’s fees for DME that could lead to inappropriately high payments.30 First, Medicare does not know what specific products it pays for when its claims administration contractors process claims for DME. DME products with similar functions or purposes are grouped together, with Medicare paying the same amount for any product in the group. These groups of DME products often represent a broad range of product types, quality, and market prices, but claims only indicate a product’s group and not the specific item. The second underlying problem with

29Medicare’s home health care benefit enables certain beneficiaries with post-acute-care needs and chronic conditions to receive care in their homes. For beneficiaries who qualify, Medicare will pay for skilled nursing, therapy, and home health aide visits under the home health benefit. See Medicare Home Health Care: Prospective Payment System Could Reverse Recent Declines in Spending (GAO-HEHS-00-176, September 8, 2000).

30See Medicare: Need to Overhaul Costly Payment System for Medical Equipment and Supplies (GAO/HEHS-98-102, May 12, 1998).
Medicare’s DME payment system is that the fee schedule allowances for DME are often out of line with current market prices. Until recently, the process for adjusting DME payments was very cumbersome. Medicare contractor representatives told us that they do not change the fee schedule allowances to reflect market prices for DME; rather the fees are typically only adjusted for inflation annually. As a result, payment levels may not reflect changes in technology and other factors that could significantly affect market prices.

### Private Payers Negotiate Prices, Other Public Payers Rely on Market-Based Benchmarks to Establish Payments for Drugs

Private and public payers use a variety of mechanisms to determine payments for drugs and their administration. Although varied, these mechanisms can generally be categorized as negotiated or contracted prices and fee schedules based on reference or benchmark prices. Private payers can negotiate with pharmacies, other suppliers, and manufacturers, either directly or through agents, to secure discounted prices and rebates that are often based on volume or market share. They or their agents also may negotiate with providers and suppliers to establish payments for services related to providing drugs. Some public programs, such as VA, can purchase drugs at FSS prices, which are linked to market prices. State Medicaid programs often use fee schedules based on AWP or wholesale acquisition cost (WAC) to reimburse providers for outpatient drugs provided under their prescription drug benefit, but receive statutorily guaranteed manufacturers’ rebates on drugs that are derived from actual transaction data. The rebates are based in part on AMP. In contrast to Medicare’s payment for drugs, both the FSS and the AMP are determined under a statutory methodology and are based on actual market prices that can be verified. In some instances, VA and Medicare have also achieved savings by setting prices through competition.

### Private Sector Purchasers Use Contracting and Market Power to Purchase Drugs

Large private health plans or their agents typically negotiate with providers the terms and conditions of payments for drugs and their delivery or administration. In general, private health plans may negotiate with preferred or network providers to establish payments for physician-provided drugs. Managed care plans reported that the terms of their provider contracts vary considerably. Under some contracts, the plan may

---

31Private health plans may designate a group of preferred or network providers to deliver services to plan beneficiaries for specified payments. With some health plans, beneficiaries may obtain services from another provider but may then be liable for the difference between what that provider charges and what the plan pays.
pay the physician a specified fee for the drug and its administration. Under others, the plan may pay participating physicians a capitated rate, placing them at financial risk for costs of a range of services, including physician-supplied drugs and their administration.

A large health-plan-owned pharmacy supplier reported a somewhat different arrangement. It buys injectible drugs directly from manufacturers and wholesalers and supplies them to the plan’s physicians. The plan contracts to pay the physicians separately for administering the drugs. The plan’s pharmacy benefits manager told us that the plan became a more aggressive purchaser of physician-provided drugs when it appeared that physicians were being overpaid for these products under an AWP-based reimbursement system. For drugs administered through DME, representatives of infusion and inhalation therapy providers indicated that while some plans may pay an all-inclusive global fee for these therapies, the most common arrangement is for private health plans to make per diem payments for pharmacy services and delivery and separate payments for the drug and nursing services, which, under certain conditions, Medicare covers under the home health benefit.

Private health plans commonly contract with pharmacy benefits managers (PBM) to manage their outpatient drugs dispensed through a retail or mail order pharmacy. PBMs negotiate contracts with retail pharmacies, which usually include discounted prices for the drugs and fees for dispensing the drugs. PBMs may obtain rebates from drug manufacturers. These discounts or rebates are often based on the volume of individual drugs purchased and may be independent of the arrangements between plans and the third parties supplying drugs to beneficiaries such as physicians or pharmacies. Plans often use formularies, lists of preferred drugs that may have lower beneficiary cost sharing, as a means of increasing use of selected drugs.32

---

32Formularies are lists of prescription drugs, grouped by therapeutic class, that health plans or insurers prefer and may encourage physicians to prescribe and beneficiaries to use. A particular product may be included on a formulary because of its medical value or because a favorable price was negotiated with the manufacturer.
The FSS for pharmaceuticals, administered by VA, is a list of products and their prices available to federal entities that purchase prescription drugs. Manufacturers must agree to supply drugs at these prices in order to have their products covered and paid for by Medicaid programs. The FSS price is intended to equal or better the price that the manufacturer offers its most-favored nonfederal customer under comparable terms and conditions. To determine the most-favored customer price, manufacturers provide VA information on price discounts and rebates offered to domestic customers and the terms and conditions involved, such as length of contract periods and ordering and delivery practices. The information used to determine the FSS price is reviewed by VA's OIG.

Agencies using the FSS generally provide drugs directly to beneficiaries through their own pharmacies and facilities.

Medicaid programs act as third-party payers, like Medicare, in reimbursing physicians and pharmacies for drugs. Most Medicaid programs reimburse pharmacies using formulas based on a percentage discount from AWP plus a dispensing fee or a percentage markup over WAC plus a dispensing fee. WAC is the list price a wholesaler pays to a manufacturer, but it does not include discounts that may affect the net price. WAC is not defined in law, and like AWP is determined by the manufacturer. Medicaid programs receive rebates based on net market prices. Under a provision of the Social Security Act added by the Omnibus Budget Reconciliation Act of 1990 (OBRA), Medicaid programs receive a rebate from manufacturers based on either AMP or the manufacturer's “best price” to a private purchaser. AMP is defined in federal law as the average price (including cash discounts and other price reductions) paid to drug manufacturers by

---

**Other Public Programs Use Market-Based Reference Prices and Competition to Establish Payments or Rebates**

---

33 48 C.F.R. Sec. 538.270.

34 48 C.F.R. Sec. 538.270.

35 Because the terms and conditions of commercial sales vary, there may be legitimate reasons why the government does not always obtain the most-favored customer price. Hence, under the General Services Administration regulations, VA may accept a higher price if it determines that (1) the price offered to the government is fair and reasonable and (2) awarding the contract is otherwise in the best interest of the government.

36 Medicaid dispensing fees ranged from $2 to over $6 per prescription in 2000. PBMs at private health plans can negotiate even lower dispensing fees that plans pay pharmacies through their ability to restrict their pharmacy networks.

U.S. wholesalers for drugs distributed to the “retail class of trade.” AMP is thus a measure of actual transaction prices between wholesalers and manufacturers. “Best price” is also defined in federal law as the lowest price (including cash discounts and other price reductions) available from the manufacturer to any U.S. wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or government entity, with some exceptions. Manufacturers currently report AMPs and “best prices” to CMS in order to participate in Medicaid. CMS can survey manufacturers’ sales information to ensure that AMP and “best price” computations are correct. However, the Social Security Act requires that CMS maintain the confidentiality of this pricing information and it is therefore not publicly available.

Public payers have made several attempts to use competition to obtain more favorable prices for drugs. VA has used a competitive bidding process to obtain national contracts for selected drugs at prices that are even lower than FSS prices. VA identified drugs regarded as therapeutically equivalent and sought contracts from manufacturers for low prices in exchange for VA including only one drug of each type on its national formulary. VA contract prices in 2000 averaged 33 percent lower than corresponding FSS prices.

The Balanced Budget Act of 1997 authorized HCFA to conduct several limited-scale demonstration projects to evaluate competitive bidding’s applicability to the Medicare program. In one of these demonstration projects currently under way in San Antonio, Texas, suppliers bid to provide inhalation drugs, such as albuterol, to Medicare beneficiaries. While Medicare normally allows any qualified provider to participate in the program, under the demonstration only those 11 bidders that were selected can participate. In exchange for restricting their choice of providers, beneficiaries have no liability for differences between what suppliers charge and what Medicare pays. Preliminary CMS information suggests savings of approximately 26 percent on these inhalation drugs in the San Antonio competitive bidding demonstration.

**Conclusions**

Medicare’s method for establishing drug payment levels is flawed. In tying its payment to AWP, a price that may be neither an average nor what wholesalers charge, Medicare has been paying much more than providers’

---

38Section 1927(k)(1) of the Social Security Act (classified to 42 U.S.C. Sec. 1396r-8(k)(1)).
likely acquisition costs. Medicare’s AWP-based methodology does not incorporate information on actual transaction prices, such as that used by VA in establishing FSS prices or the AMPs used to calculate Medicaid drug rebates.

Our findings strongly suggest that Medicare should revise its drug payment policies. Payments for the drugs themselves should closely parallel market prices that providers pay to acquire drugs. The program needs to use information on actual market prices net of rebates and discounts, similar to information currently available to VA to establish the FSS and to HHS to determine the Medicaid rebates. Although the widely available prices we report here are often substantially below Medicare’s payment, certain providers may be able to obtain even greater discounts. However, the lowest prices, used in setting the FSS prices and Medicaid rebates, may not be available to all Medicare providers for all Medicare-covered drugs. To better ensure that beneficiary access is not compromised, in setting payment levels it is important to be mindful that providers’ ability to secure discounts likely varies.

Physicians and other providers acknowledge that payments for drugs are higher than their costs, but contend that profits on the drugs compensate for what they regard as underpayments for their administration. It should be a principle of Medicare payment policy to pay for each service appropriately and not to rely on potential overpayments for some services to offset potential inadequate payments for complementary services. Consequently, separate payments for administration and delivery should be made, with those payments appropriately reflecting the variation associated with how the drugs are provided. Hence, different methods of determining drug delivery and administration payments may be necessary for different types of drugs.

Some benefits of competition for securing selected drugs under certain circumstances have been demonstrated by VA and by Medicare in the San Antonio demonstration. Medicare’s experience is rather limited and involves a very small number of drugs. Nevertheless, how the use of competitive bidding might be expanded without compromising beneficiary access is worth exploring.
In order to improve the accuracy of Medicare payments for drugs and related services, we are recommending that the Administrator of CMS take the following actions.

- Establish Medicare payment levels for part-B prescription drugs and their delivery and administration that are more closely related to their costs. Payments for drugs should be set at levels that reflect actual market transaction prices and the likely acquisition cost to providers. To accomplish this, the Administrator should consider how information on market transactions already available to HHS or VA may be used as a benchmark for Medicare payment levels. If the Administrator determines that legislative action would be required to use such information in setting Medicare reimbursements, he should seek this action immediately.
- Examine the benefits and risks of expanding the current competitive bidding demonstration projects for drugs covered under part B.
- Institute a process to monitor access to Medicare part B-covered drugs to ensure that payment changes do not negatively affect access for particular drugs, or groups of beneficiaries or in certain geographic areas.

CMS noted that our findings confirmed the results of studies by the HHS OIG that indicated that Medicare payments for drugs are substantially higher than their actual acquisition costs. CMS agreed that Medicare should appropriately pay for both part B-covered drugs and the services required to furnish them. CMS’s comments appear in their entirety as appendix II.

We are sending copies of this report to the Administrator of CMS and interested congressional committees. We will make copies available to others on request.

If you or your staffs have any questions about this report, please call me at (202) 512-7119 or James Mathews at (202) 512-9427. Major contributors to this report were Ginny Hsieh, Dina Kirschenbaum, Kathryn Linehan, and Theresa Thompson.

Laura A. Dummit
Director, Health Care—Medicare Payment Issues
List of Congressional Committees

The Honorable Max Baucus
Chairman
The Honorable Charles E. Grassley, Jr.
Ranking Minority Member
Committee on Finance
United States Senate

The Honorable Bill Thomas
Chairman
The Honorable Charles B. Rangel
Ranking Minority Member
Committee on Ways and Means
House of Representatives

The Honorable W.J. “Billy” Tauzin
Chairman
The Honorable John D. Dingell
Ranking Minority Member
Committee on Energy and Commerce
House of Representatives
In conducting this study, we interviewed officials at CMS, VA, HHS OIG, and DOJ. We also interviewed and solicited information about drug acquisition costs and costs related to drug administration from professional associations representing physicians and other providers with a major stake in our evaluation. We requested price data on specific drugs from major pharmaceutical wholesalers, oncology specialty wholesalers, and GPOs, none of which responded to our request by the time we finalized this report. We also requested price data from specialty pharmacies, DME pharmacy suppliers, a national oncology clinic chain, and physicians, including physicians we identified as billing for low volumes of Medicare-covered drugs. We interviewed representatives from large managed care organizations and their agents regarding the methods they used to purchase or pay for pharmaceuticals as well as the purchase prices they were able to obtain. We also interviewed staff at the companies that publish major price reporting compendia that collect and report average wholesale prices for drugs. We conducted quantitative analyses using data from CMS and other sources. We did our work in accordance with generally accepted government auditing standards from January through September 2001.

To determine the drugs and biological products that accounted for the most Medicare spending and volume, we used 1999 data from BESS. We also used BESS data to determine spending and volume by part B carrier, place of service, and specialty. All analyses using BESS data excluded data on services supplied in Puerto Rico and the U.S. Virgin Islands and payments made on behalf of the Railroad Retirement Board.

We excluded four HCPCS-coded products from our analysis because of problems obtaining accurate pricing information or, in one case, because the code was not specific enough to link to a given product. From the high-volume/high-expenditure HCPCS codes that were chosen for our study, we evaluated pricing information for the NDCs that were used to determine reimbursement rates for that HCPCS. We asked the Medicare part B carriers with the highest allowed drug charges in each region and the DME regional carriers to provide the NDCs they used to calculate reimbursement for 31 HCPCS codes. Because carriers may use somewhat different groups of NDCs, we included all of the NDCs in our analysis of prices for each HCPCS we analyzed.

We obtained widely available drug prices for selected HCPCS for 2000 and 2001 from several wholesalers’ and GPOs’ price lists, which we obtained from a government agency and from providers. The AWPs were obtained
from the 2000 Drug Topics’ Red Book and the 2001 Drug Topics’ Red Book CD-ROM by NDC for each year.

To identify physicians who billed for low volumes of multiple drugs, we examined all Medicare part B drug claims from 1999 and identified 1,115 physicians who met our definition of a low-volume Medicare biller for cancer drugs in 1999, and selected a random sample of 108 physicians. We defined low-volume biller as a physician who billed for between the 10th and 25th percentile of total allowed units for three or more of the following drugs: Dexamethasone sodium phosphate, Leuprolide acetate, Rituximab, Goserelin acetate, Docetaxel, Filgrastim (480 mcg), Pamidronate disodium, Filgrastim (300 mcg), Paclitaxel, Irinotecan, Carboplatin, Gemcitabine HCl, Dolasetron mesylate, Granisetron HCl, Leucovorin calcium, Epoetin alpha for non-ESRD use, and Ondansetron HCl. We then merged the claims file physician sample with the Unique Physician Identification Number directory to get names and addresses of providers. We received 74 prices for NDCs for 16 HCPCS-coded drugs from 14 low-volume billers. An additional 37 physicians were hospital-based, operated out of large practices, or worked for large nationally owned chain oncology practices. We could not contact 36 physicians for whom we could not find correct telephone numbers. Twenty practices declined to provide us with information or did not provide information in time to be included in this report. One practice indicated it did not purchase drugs.
Appendix II: Comments From the Centers for Medicare and Medicaid Services

DEPARTMENT OF HEALTH & HUMAN SERVICES
Health Care Financing Administration

The Administrator
Washington, D.C. 20201

DATE: SEP 19 2001

TO: Laura A. Dummit
Director, Health Care—Medicare Payment Issues
General Accounting Office

FROM: Thomas A. Scully
Administrator
Centers for Medicare & Medicaid Services


The GAO confirms the findings of its previous reports along with previous reports from the Office of Inspector General that Medicare's payments for drugs are substantially higher than the actual costs to physicians and other providers acquiring these drugs. Physicians and other providers indicate that while Medicare overpays for the cost of the drugs, Medicare payments sometimes do not adequately compensate for services related to furnishing the drugs.

We agree with GAO that Medicare needs to pay appropriately for all Medicare benefits, including the drugs we currently cover, as well as, the services required to furnish these drugs. We look forward to working with the Congress and GAO to address this important issue.

The Health Care Financing Administration (HCFA) was renamed to the Centers for Medicare & Medicaid Services (CMS). We are exercising fiscal restraint by exhausting our stock of stationery.
The first copy of each GAO report is free. Additional copies of reports are $2 each. A check or money order should be made out to the Superintendent of Documents. VISA and MasterCard credit cards are also accepted.

Orders for 100 or more copies to be mailed to a single address are discounted 25 percent.

Orders by mail:
U.S. General Accounting Office
P.O. Box 37050
Washington, DC  20013

Orders by visiting:
Room 1100
700 4th St., NW (corner of 4th and G Sts. NW)
Washington, DC  20013

Orders by phone:
(202) 512-6000
fax: (202) 512-6061
TDD (202) 512-2537

Each day, GAO issues a list of newly available reports and testimony. To receive facsimile copies of the daily list or any list from the past 30 days, please call (202) 512-6000 using a touchtone phone. A recorded menu will provide information on how to obtain these lists.

Orders by Internet
For information on how to access GAO reports on the Internet, send an e-mail message with “info” in the body to:

Info@www.gao.gov

or visit GAO’s World Wide Web home page at:

http://www.gao.gov

Contact one:

- E-mail: fraudnet@gao.gov
- 1-800-424-5454 (automated answering system)